221 related articles for article (PubMed ID: 35470756)
1. Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFR
O Aboelez M; Belal A; Xiang G; Ma X
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1196-1211. PubMed ID: 35470756
[TBL] [Abstract][Full Text] [Related]
2. Microwave-assisted synthesis, spectroscopic characterization, and biological evaluation of fused thieno[2,3-d]pyrimidines as potential anti-cancer agents targeting EGFR
Aboelez MO; Kamel MS; Belal A; El Badry Abdel-Aziz A; Abourehab MAS; Abdel-Ghany H; A El Hamd M; El-Remaily MAEAA
Mol Divers; 2023 Apr; 27(2):901-917. PubMed ID: 35780205
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
[TBL] [Abstract][Full Text] [Related]
4. New Anticancer Theobromine Derivative Targeting EGFR
Elkaeed EB; Yousef RG; Elkady H; Alsfouk AA; Husein DZ; Ibrahim IM; Metwaly AM; Eissa IH
Molecules; 2022 Sep; 27(18):. PubMed ID: 36144596
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
6. Design and Synthesis of Non-Covalent Imidazo[1,2-
Kumar M; Joshi G; Arora S; Singh T; Biswas S; Sharma N; Bhat ZR; Tikoo K; Singh S; Kumar R
Molecules; 2021 Mar; 26(5):. PubMed ID: 33803355
[TBL] [Abstract][Full Text] [Related]
7. Exploration of thiazolidine-2,4-diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations.
Aziz NAAM; George RF; El-Adl K; Mahmoud WR
Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200465. PubMed ID: 36403198
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, and Antiproliferative Activity of New 5-Chloro-indole-2-carboxylate and Pyrrolo[3,4-
Al-Wahaibi LH; Mohammed AF; Abdelrahman MH; Trembleau L; Youssif BGM
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770936
[TBL] [Abstract][Full Text] [Related]
9. Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR
Abo Al-Hamd MG; Tawfik HO; Abdullah O; Yamaguchi K; Sugiura M; Mehany ABM; El-Hamamsy MH; El-Moselhy TF
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2241674. PubMed ID: 37548154
[TBL] [Abstract][Full Text] [Related]
10. Computational Design, Synthesis, and Bioevaluation of 2-(Pyrimidin-4-yl)oxazole-4-carboxamide Derivatives: Dual Inhibition of EGFR
Raghunath Khedkar N; Sindkhedkar M; Joseph A
Bioorg Chem; 2024 Feb; 143():107027. PubMed ID: 38096682
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, apoptotic, and antiproliferative effects of 5-chloro-3- (2-methoxyvinyl)-indole-2-carboxamides and pyrido[3,4-b]indol-1-ones as potent EGFR
Al-Wahaibi LH; Mohammed AF; Abdel Rahman FES; Abdelrahman MH; Gu X; Trembleau L; Youssif BGM
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2218602. PubMed ID: 37254958
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel heptamethine cyanine dye-erlotinib conjugates as antitumor agents.
Yang X; Hou Z; Wang D; Mou Y; Guo C
Bioorg Med Chem Lett; 2020 Dec; 30(23):127557. PubMed ID: 32949719
[TBL] [Abstract][Full Text] [Related]
13. Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights.
Al-Warhi T; El Kerdawy AM; Said MA; Albohy A; Elsayed ZM; Aljaeed N; Elkaeed EB; Eldehna WM; Abdel-Aziz HA; Abdelmoaz MA
Drug Des Devel Ther; 2022; 16():1457-1471. PubMed ID: 35607598
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M).
Shaheen MA; El-Emam AA; El-Gohary NS
Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080
[TBL] [Abstract][Full Text] [Related]
15. Discovery of new 1
Gaber AA; Sobhy M; Turky A; Abdulwahab HG; Al-Karmalawy AA; Elhendawy MA; Radwan MM; Elkaeed EB; Ibrahim IM; Elzahabi HSA; Eissa IH
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2283-2303. PubMed ID: 36000168
[TBL] [Abstract][Full Text] [Related]
16. Effective degradation of EGFR
Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
[TBL] [Abstract][Full Text] [Related]
18. Development of Novel Class of Phenylpyrazolo[3,4-
Aljohani AKB; El Zaloa WAZ; Alswah M; Seleem MA; Elsebaei MM; Bayoumi AH; El-Morsy AM; Almaghrabi M; Awaji AA; Hammad A; Alsulaimany M; Ahmed HEA
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834474
[TBL] [Abstract][Full Text] [Related]
19. 3'-(4-(Benzyloxy)phenyl)-1'-phenyl-5-(heteroaryl/aryl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazole]-2-carboxamides as EGFR kinase inhibitors: Synthesis, anticancer evaluation, and molecular docking studies.
Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Pottoo FH; Jha M
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900262. PubMed ID: 32003485
[TBL] [Abstract][Full Text] [Related]
20. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]